esophageal cancer
New York State DOH Approves Castle Biosciences' Barrett’s Esophagus Test
The TissueCypher assay is designed to identify patients with Barrett's esophagus who are at risk of progressing to esophageal cancer.
CHMP Recommends BeiGene's Tevimbra for First-Line PD-L1-Positive Gastric, Esophageal Cancers
The recommendation was based on results from two Phase III trials showing that Tevimbra plus chemo improved overall survival over chemo alone.
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
FDA Expert Panel to Consider Limiting Gastric, Esophageal Cancer Immunotherapies to PD-L1 Expressors
The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all-comers and in PD-L1-positive subgroups.
Lucid Diagnostics Partners With Front Line Mobile to Promote Esophageal Cancer Test
Working with the first responder medical care provider, Lucid is planning high-volume testing events among firefighters and other frontline workers with elevated risk.